Fidelity Investments
AVIR icon

Fidelity Investments’s Atea Pharmaceuticals AVIR Stock Holding History

Fidelity Investments’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.8M Buy
12,004,064
+53,292
+0.4% +$265K ﹤0.01% 1477
2026
Q1 		$64.3M Buy
11,950,772
+2,271,776
+23% +$10.4M ﹤0.01% 1339
2025
Q4 		$34.6M Buy
9,678,996
+3,856,223
+66% +$12.3M ﹤0.01% 1578
2025
Q3 		$16.9M Buy
5,822,773
+103,015
+2% +$352K ﹤0.01% 1801
2025
Q2 		$20.6M Sell
5,719,758
-298,261
-5% -$890K ﹤0.01% 1688
2025
Q1 		$18M Sell
6,018,019
-407,206
-6% -$1.27M ﹤0.01% 1715
2024
Q4 		$21.5M Sell
6,425,225
-193,072
-3% -$642K ﹤0.01% 1700
2024
Q3 		$22.2M Buy
6,618,297
+182,174
+3% +$661K ﹤0.01% 1673
2024
Q2 		$21.3M Buy
6,436,123
+657,094
+11% +$2.45M ﹤0.01% 1623
2024
Q1 		$23.3M Buy
5,779,029
+428,370
+8% +$1.68M ﹤0.01% 1592
2023
Q4 		$16.3M Sell
5,350,659
-1,101,891
-17% -$3.34M ﹤0.01% 1692
2023
Q3 		$19.4M Sell
6,452,550
-2,044,756
-24% -$6.96M ﹤0.01% 1591
2023
Q2 		$31.8M Sell
8,497,306
-3,076,073
-27% -$11.5M ﹤0.01% 1440
2023
Q1 		$38.8M Sell
11,573,379
-164,030
-1% -$665K ﹤0.01% 1353
2022
Q4 		$56.5M Sell
11,737,409
-751,337
-6% -$3.8M 0.01% 1213
2022
Q3 		$71.1M Sell
12,488,746
-50,729
-0.4% -$388K 0.01% 1089
2022
Q2 		$89M Sell
12,539,475
-40,316
-0.3% -$275K 0.01% 1021
2022
Q1 		$90.8M Buy
12,579,791
+114,382
+0.9% +$777K 0.01% 1106
2021
Q4 		$111M Buy
12,465,409
+48,876
+0.4% +$762K 0.01% 1056
2021
Q3 		$435M Buy
12,416,533
+6,003
+0% +$167K 0.03% 480
2021
Q2 		$267M Buy
12,410,530
+1,651,735
+15% +$49.6M 0.02% 697
2021
Q1 		$664M Buy
10,758,795
+4,311,103
+67% +$291M 0.06% 330
2020
Q4 		$269M Buy
+6,447,692
New +$208M 0.02% 628

Other funds holding AVIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments's AVIR Position: Q2 2026 in Review

Fidelity Investments increased its Atea Pharmaceuticals (AVIR) stake by 0.45% in Q2 2026, buying an estimated $265K and bringing the position to 12,004,064 shares worth $55.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1477.

Fidelity Investments first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $664M in Q1 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Fidelity Investments held 12,004,064 shares of Atea Pharmaceuticals worth $55.8M as of Q2 2026.
  • Fidelity Investments bought 53,292 Atea Pharmaceuticals shares in Q2 2026, an estimated $265K.
  • Atea Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1477 holding.
  • Fidelity Investments first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Fidelity Investments's Atea Pharmaceuticals position peaked at $664M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.